EphA3 CAR T cells are effective against glioblastoma in preclinical models.

ABSTRACT:

Background

Adoptive T-cell therapy targeting antigens expressed in glioblastoma has emerged as a potential therapeutic strategy to prevent or delay recurrence and prolong overall survival in this aggressive disease setting. Ephrin receptor A3 (EphA3), which is highly expressed in glioblastoma; in particular, on the tumor vasculature and brain cancer stem cells, is an ideal target for immune-based therapies.

Methods

We have designed an EphA3-targeted chimeric antigen receptor (CAR) using the single chain variable fragment of a novel monoclonal antibody, and assessed its therapeutic potential against EphA3-expressing patient-derived glioblastoma neurospheres, organoids and xenografted glioblastoma tumors in immunodeficient mice.

Results

In vitro expanded EphA3 CAR T cel

SUBMITTER: Martins P 

PROVIDER: S-EPMC11308892 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature